UMEM Research Studies

An ED based survey of non-critically ill patients asking them questions that relate to the following domains: Where they get primary care (or any health care), current mask usage and availability, receptiveness to immunization with a COVID-19 vaccine, barriers and concerns about immunization with a COVID-19 vaccine.

A prospective, non blinded, non randomized trial conducted at the University of Maryland Medical Center Downtown Campus (UMMC) located in Baltimore, Maryland that aims to evaluate patient engagement in a program to monitor home pulse oximetry and development of symptoms for patients with or under investigation for infection with SARS-CoV-2. 

A Phase 2 randomized, double-blinded, placebo-controlled multicenter study designed to evaluate BLD-2660 as add-on to standard of care (SOC) therapy in hospitalized subjects with recently diagnosed COVID-19 compared to SOC treatment. The study will include a Screening period, a Treatment period, and a Follow-up period.

A multi-centered, double blinded clinical trial to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment in participants with Influenza A who are at risk of developing complications. 

A multi-centered, double blinded clinical trial to evaluate the efficacy/safety of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment in hospitalized participants with Influenza A.

A phase III randomized single blinded study that aims to compare the two analgesic protocols recommended by the NHLBI for treating Vaso-occlusive episodes in the Emergency Department.

A prospective, nonblinded, randomized controlled trial that aims to assess whether an FDA-approved rapid turnaround test (RTAT) for Neisseria gonorrheae and Chlamydia trachomatis infections will lead to more appropriate antibiotic prescription in the emergency department. 

A single-center, non-randomized, non-blinded feasibility study to evaluate the performance, safety and tolerability of the Percutaneous Ultrasound Gastrostomy (PUG) procedure that utilizes a novel device in conjunction with widely available ultrasound technology.

A randomized, double-blinded, placebo-controlled, adaptive phase 1/2/3 master protocol will assess the safety, tolerability, and efficacy of REGN10933+REGN10987 and REGN10989 in ambulatory patients with COVID-19. The multicenter conduct of this study will enable generalizable evidence of the safety, tolerability, and efficacy of these investigational mAbs for COVID-19.

This study aims to evaluate the impact of LY3819253 and LY3819253 in combination with LY3832479 on viral clearance and clinical outcomes in participants with mild to moderate COVID-19 illness. The data from this study will inform decisions for the clinical development of these neutralizing IgG1mAbs. 

The aim of the study is to evaluate the impact of LY3819253 alone, LY3853113 alone, LY3819253 + LY3832479, LY3853113+ LY3819253 + LY3832479, and LY3819253 + VIR7831 on viral clearance and clinical outcomes in participants with COVID-19 illness. 

The overall goal of this study is to determine whether the levels of microparticles may be elevated in patients with angioedema that develops as a result of the use of the class of blood pressure medications, ACE inhibitors.